Nasdaq
$0.3641▼ 0.38%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $4.9MShares out 13.6M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
27- 2d agoAfter-hours26.10.23 05:003Ownership#●●●
Evogene Ltd.
Evogene Ltd. executive Adler Oz has filed a Form 3, reporting their initial statement of beneficial ownership of company securities as of October 6, 2026. This filing serves as an official disclosure of the executive's equity holdings.…more
$0.3641-0.38%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 2d agoAfter-hours26.10.23 05:003Ownership
Evogene Ltd.
Evogene Ltd. insider Adi Zuloff-Shani filed a Form 3 on October 22, 2026, reporting their initial statement of beneficial ownership of securities as of October 6, 2026. This filing serves as a formal disclosure of the insider's equity position in the company.…more
$0.3641-0.38%vs prev closeView filingShare - 10.6After-hours26.10.07 05:10SCHEDULE 13D/AOwnership
Evogene Ltd.
Evogene entered into a cooperation agreement on October 6, 2026, with major shareholders L.I.A. Pure Capital and Invest Pro to resolve a proxy contest. Under the agreement, two directors resigned, two shareholder-nominated directors were appointed, and the company will hold a general meeting to approve the agreement and additional director appointments. The company agreed to halt new share issuances for 60 days, while the shareholders withdrew their special tender offer and committed to mutual non-disparagement.…more
$0.3641-0.38%vs prev closeView filingShare
26 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.6After-hours26.10.07 05:02#●●●
Evogene Reaches Agreement With Pure Capital Group To Resolve Board Dispute…more
Evogene has reached an agreement with Pure Capital Group to resolve their board dispute by appointing new directors nominated by the group. The deal includes a 60-day standstill period during which the company will refrain from issuing new shares.…more
$0.3641-0.38%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 9.30Pre-market26.09.30 20:19
●●●●●●●● ●●●●● ●●●●●●
Evogene has been granted an extension until March 29, 2027, to regain compliance with Nasdaq's minimum bid price requirement. The company must maintain a closing share price of at least $1.00 for ten consecutive business days within this period to resolve the compliance issue.…more
$0.3641-0.38%vs prev closeShareBenzinga - 8.18Regular26.08.19 00:14
●●●●●●●● ●●●●● ●●●●●●
Evogene reported a Q2 loss per share of $0.13, beating analyst estimates, though revenue fell by over 60% compared to the previous year. While the loss narrowed, the significant drop in revenue suggests a cautious outlook on the company's financial performance.…more
$0.3641-0.38%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report